Nearly 80% of Patients with Moderate-to-Severe Atopic Dermatitis Maintained Clear or Almost Clear Skin with Lilly ' s Lebrikizumab Monthly Maintenance Dosing at Two Years

INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials